Interestingly, the spliceosome inhibitors pladienolides B and isoginkgetin could also induce BCL2L12 exon 3 skipping and inhibit the proliferation of ovarian cancer cells (Fig. S8c–f). Here, BCL2L12 is linked to ovarian carcinoma.